Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto
Rep. Price to answer questions at confirmation hearing; 22 drugmakers invest in fighting disease in poor countries; FDA approves generic of Jazz's Xyrem
CVS to sell generic EpiPen; FDA finalizes biosimilar naming rules; Pfizer wants to make a deal
Pfizer to start selling Remicade biosimilar in November; The Medicines Co.'s PCSK9 inhibitor heads to Phase-III trials; J&J's Q3 growth bolstered by autoimmune drugs
Merck launches biosimilar resource; branded insulin prices are on the rise; NICE declines to cover Opdivo
More drugmakers file lawsuits to prevent biosimilar competition; experimental dermatitis drug showeds promising results; pharma blames PBMs for price hikes
Amgen's drug is set to compete with AbbVie's Humira, which is the second-best selling drug in the U.S. in 2015.
The FDA approves an Enbrel biosimilar; Express Scripts to launch program to reduce diabetes costs; a GSK vaccine beats sales forecasts
Court clears Pfizer to move ahead with Remicade biosimilar; McDonald's yanks activity trackers over skin irritation; California drug-pricing bill pulled
Herceptin biosimilar meets endpoint in clinical trial; Roche plans to launch five new drugs over the next year; government seeks to block insurer deals
The FDA expands use for Pfizer's Prevnar 13 vaccine; an FDA panel votes in support of Novartis biosimilar; U.S. healthcare spending rises 5.5% in 2015
Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.
A Sermo poll asked physicians: Do you feel biosimilars will prove safe and effective enough for you to prescribe them when more become available?"
Investigation says Oxycontin wears off sooner than it claims; PBMs and insurers anticipate high biosimilar prices; Valeant forms pricing committee
The FDA has approved two biosimilars, but questions remain about how quickly providers and patients in the U.S. will adopt them.
The company said growth in its immunology portfolio offset declining Olysio sales.
Pfizer and Allergan call off merger; the FDA approves second biosimilar; NEJM comes under fire
There are 23 biosimilars ready to file with the FDA; an FDA committee votes in favor of Parkinson's disease drug; Bloomberg funds new immunotherapy center
Aegerion slashes workforce; GSK president says downward pressure on drug prices is here to stay; Novartis acquires European rights to Remicade biosimilar
The FDA is set to announce its decision on the drug in April.
SEC is investigating Salix Pharmaceuticals; FDA adcomm recommends approval of Remicade biosimilar; Medicare considers payment changes
The FDA to review biosimilar Remicade; lawmaker looks at panelists' ties to painkiller manufacturers; Novartis signs risk-sharing contracts for Entresto
Johnson & Johnson collaborates with biotech on diabetes stem-cell treatment; the FDA warms up to Remicade biosimilar; Woodcock warns about biosimilar backlog
The FDA approves Lilly's Lantus follow-on biologic; AstraZeneca buys majority stake in Acerta Pharma; Shkreli arrested on securities fraud charges
Califf defends his past; Drug spending to increase by 4%-7% per year through 2020; Samsung Bioepis's Enbrel biosimilar faces decision-date Friday
Keytruda approved in non-small cell lung cancer; Enbrel biosimilar inches closer to approval; study finds no link between autism and vaccines
Sandoz plans to take a branded approach as it launches the first FDA-approved biosimilar product.
Novartis launches Zarxio, the first US biosimilar; UCB sells its generic business; one-third of children with ADHD are diagnosed before they turn six
The motion denied Amgen's bid for a temporary injunction that would have prevented the launch of Zarxio, the first FDA-approved biosimilar and a competitor to Amgen's Neupogen.
Less than half of 300 doctors polled in a QuantiaMD survey could name a biosimilar that's under consideration for approval, and only 17% said they're very likely to prescribe one.
- Deloitte taps Havas Lynx's Mickelberg as MD
- Five things for pharma marketers to know: Wednesday, February 22, 2017
- Five things for pharma marketers to know: Thursday, February 23, 2017
- Five things for pharma marketers to know: Tuesday, February 21, 2017
- How VAYA Pharma used Facebook ads for its ADHD campaign
- Guidemark Health's Sophy Regelous on why small budgets are increasing
- What uncertainty? 72% of health marketers say 2017 budgets are up
- Publicis Health formalizes new name, promotes 3 execs
- Is the Trump Administration the Cure the FDA Needs?
- Five things for pharma marketers to know: Friday, February 24, 2017